Results 201 to 210 of about 3,132 (216)

Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology, 2023
Keiko Kataoka, Masashi Ogasawara
exaly  

Short-term outcomes of intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology, 2023
Kosuke Nakamura, Hidetaka Matsumoto, Junki Hoshino   +2 more
exaly  

Vitritis following intravitreal faricimab: a retrospective monocentric analysis

Graefe's Archive for Clinical and Experimental Ophthalmology
Alexandre Bourdin, S. Y. Cohen, S. Nghiem-Buffet, Jérôme Smadja, M. Paques, F. Fajnkuchen, Sarah Mrejen   +6 more
semanticscholar   +1 more source

Aflibercept/faricimab

Reactions Weekly
  +4 more sources

One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration

Japanese Journal of Ophthalmology
H. Matsumoto, Junki Hoshino, Kosuke Nakamura, Hideo Akiyama   +3 more
semanticscholar   +1 more source

Rates of Ocular Adverse Events after Intravitreal Faricimab Injections

Ophthalmology Retina
Jason Hsu, Samir Patel, Bita Momenaei
exaly  

Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab

Ophthalmology Retina
Michael Grinton, Raffaele Raimondi, David Steel   +2 more
exaly  

Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration

Ophthalmology Retina
Michael Klufas, Allen Chiang, Asad Durrani   +2 more
exaly  

Bevacizumab/faricimab

Reactions Weekly
openaire   +1 more source

Real-World 1-Year Outcomes of Treatment-Intensive Neovascular Age-Related Macular Degeneration Switched to Faricimab

Ophthalmology Retina
Praveen Patel, Sobha Sivaprasad, Evangelia Chalkiadaki   +2 more
exaly